File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B

TitleWeek 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B
Authors
Lai, CLAhh, SHLee, KSUm, SHCho, MYoon, SKLee, JWPark, NHKweon, YOSohn, JHLee, JKim, JAHan, KHYuen, MF
KeywordsMedical sciences
Gastroenterology
Issue Date2011
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24 How to Cite?
DOI: http://dx.doi.org/10.1002/hep.24666
AbstractBACKGROUND: LB80380, a novel nucleotide analogue, is effective and safe in chronic hepatitis B(CHB) patients with lamivudine-resistant mutations, with doses above 90 mg daily. AIM: To compare the efficacy and safety of LB80380 with entecavir in treatment-naive CHB patients up to week 48 of therapy. METHODS: 115 CHB patients fulfilling the following criteria were recruited from Hong Kong and Korea: (1) HBsAg positive for …
DescriptionThis journal suppl. contain abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011
Poster Presentation
Persistent Identifierhttp://hdl.handle.net/10722/169370
ISSN
0270-9139
2023 Impact Factor: 12.9
2023 SCImago Journal Rankings: 5.011

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_US
dc.contributor.authorAhh, SHen_US
dc.contributor.authorLee, KSen_US
dc.contributor.authorUm, SHen_US
dc.contributor.authorCho, Men_US
dc.contributor.authorYoon, SKen_US
dc.contributor.authorLee, JWen_US
dc.contributor.authorPark, NHen_US
dc.contributor.authorKweon, YOen_US
dc.contributor.authorSohn, JHen_US
dc.contributor.authorLee, Jen_US
dc.contributor.authorKim, JAen_US
dc.contributor.authorHan, KHen_US
dc.contributor.authorYuen, MFen_US
dc.date.accessioned2012-10-18T08:51:56Z-
dc.date.available2012-10-18T08:51:56Z-
dc.date.issued2011en_US
dc.identifier.citationThe 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24en_US
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/169370-
dc.descriptionThis journal suppl. contain abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011-
dc.descriptionPoster Presentation-
dc.description.abstractBACKGROUND: LB80380, a novel nucleotide analogue, is effective and safe in chronic hepatitis B(CHB) patients with lamivudine-resistant mutations, with doses above 90 mg daily. AIM: To compare the efficacy and safety of LB80380 with entecavir in treatment-naive CHB patients up to week 48 of therapy. METHODS: 115 CHB patients fulfilling the following criteria were recruited from Hong Kong and Korea: (1) HBsAg positive for …-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatologyen_US
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleWeek 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis Ben_US
dc.typeConference_Paperen_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, MF: mfyuen@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.24666-
dc.identifier.scopuseid_2-s2.0-80054030408-
dc.identifier.hkuros211200en_US
dc.identifier.hkuros211046-
dc.identifier.volume54en_US
dc.identifier.issuesuppl. 1en_US
dc.identifier.spage1442Aen_US
dc.identifier.epage1442Aen_US
dc.publisher.placeUnited States-
dc.description.otherThe 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24-
dc.identifier.issnl0270-9139-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats